Results 1 to 10 of about 11,132 (163)
Biomedical Papers, 2020 Background: MiR150-5p has been reported to be involved in generalized myasthenia gravis, in which different cytokines play critical roles. The regulatory network of cytokines in generalized myasthenia gravis has not been fully elucidated. Our study aimed
Wenling Ao +5 more
doaj +3 more sources
Efgartigimod for patients with thymoma associated generalized myasthenia gravis during the perioperative period: a four-case report [PDF]
Frontiers in ImmunologyBackgroundThymectomy is one of the main treatments for thymoma associated myasthenia gravis, but there is a risk of acute exacerbation of myasthenia gravis symptoms during the perioperative period of thymoma.
Liuli Ren +5 more
doaj +2 more sources
Frontiers in NeurologyBackgroundDespite existing treatments of generalized myasthenia gravis (gMG), there remains a need for more effective therapies with fewer side effects.
Xiaodong Song +6 more
doaj +3 more sources
Frontiers in Pediatrics, 2022 Myasthenia gravis is an organ-specific autoimmune disease. Currently there is no universal guidelines for childhood-onset myasthenia gravis, therefore, treatment strategies are usually based on the guidelines from adult myasthenia gravis patients.
Lifen Yang +6 more
doaj +1 more source
American Journal of Ophthalmology Case Reports, 2023 Purpose: This is a case of myasthenic incomplete ophthalmoplegia mimicking a partial cranial nerve 3 palsy both subjectively and objectively improving after treatment with eculizumab.
Sara L. Weidmayer, Gary Gallagher
doaj +1 more source
Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis
Neurology and Therapy, 2023 This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare ...
Tuan Vu +9 more
doaj +1 more source
Tatalaksana terkini pada miastenia gravis
Majalah Kedokteran Andalas, 2022 Myasthenia gravis (MG) is a disorder of the neuromuscular junction that causes fluctuating muscle weakness. The etiology of this disease is due to the presence of antibodies that attack acetylcholine receptors on the postsynaptic membrane (autoimmune ...
Lydia Susanti
doaj +1 more source
Concentric Needle Jitter in 97 Myasthenia Gravis Patients
Frontiers in Neurology, 2020 Objectives: To estimate the jitter parameters (single-fiber electromyography) in myasthenia gravis patients mostly by electrical activation in Frontalis, Orbicularis Oculi, and Extensor Digitorum muscles using a concentric needle electrode.Methods ...
João Aris Kouyoumdjian +2 more
doaj +1 more source
Features of depression development in myasthenia gravis.
Medičnì Perspektivi, 2020 The relative risk of developing depression in myasthenia gravis is 2.14 times higher than in the general population. The features of depression in myasthenia patients remain poorly understood and need to be clarified.
O. I. Kalbus +4 more
doaj +1 more source
Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis : a subgroup analysis of the REGAIN open-label extension study [PDF]
, 2019 The terminal complement inhibitor eculizumab was shown to improve myasthenia gravis-related symptoms in the 26-week, phase 3, randomized, double-blind, placebo-controlled REGAIN study (NCT01997229).
De Bleecker, Jan +12 more
core +1 more source